Actually there’s a sunset clause for these vouchers - the FDA cannot approve thrm after 30 Sep 2024, and they seem to only apply for paediatric diseases. In that case, Ryonicil for kids could qualify for such a voucher - just wonder if it already has the rare disease designation (as Rux does - it is mentioned as potentially one of the top selling small molecule rare disease drugs by 2026).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864910/
Cell Therapy News/Articles, page-17785
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.010(0.91%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.11 | $1.07 | $4.794M | 4.399M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14500 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 141676 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |